Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

By sjmartinez • June 9, 2024

Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun;19(6):928-940. doi: 10.1016/j.jtho.2024.01.012. Epub 2024 Jan 24. PMID: 38278303.

Tags: Adverse events, Cedars Sinai DoM, chemotherapy, durvalumab, EGFR, Hematology/Oncology, Non–small cell lung cancer, Osimertinib, Publications, targeted therapy

A Multi-Analyte cfDNA-based Blood Test for Early Detection of Hepatocellular Carcinoma

Taggart DJ, Mahajan S, Gallant MA, Pinkoviezky I, Xu J, Sorg AJ, Roberts CC, Slinkov D, Gorospe EC, Mubarak A, Bhandari BR, Freilich B, Gunn[...]

The Epidemiology of Young-Onset Barrett’s Esophagus in the United States: A National Population-Based Study Using the TriNetX Database

Vasireddy AR, Chandar AK, Maravillas MA, Perez JA, Algarin Perneth SL, Kolb JM, Leggett CL, Katzka DA, Iyer PG, Gaddam S, Kamboj AK. The Epidemiology[...]

Activation of the impaired NAMPT/SIRT7/SOD2 axis restores alveolar progenitor renewal in idiopathic pulmonary fibrosis

Zhang X, Liu X, Qiao Y, Rabata A, Liu N, Yao C, Parimon T, Chen D, Hogaboam CM, Chen P, Stripp BR, Gardell SJ, Jiang[...]